Exhibit 10.74
KEY MANAGEMENT RETENTION AGREEMENT
THIS KEY MANAGEMENT RETENTION AGREEMENT (the "Agreement"), dated as of
December 5, 2001 (the "Effective Date"), is made and entered into by and between
RAYTEL MEDICAL CORPORATION, a Delaware corporation (the "Company"), and XXXX X.
XXXXXX, XX. (the "Executive").
RECITALS:
A. The Executive is currently employed, as an at-will employee, as the
Company's Vice President and Chief Financial Officer;
B. The Company is considering various potential strategic transactions
that could result in a Change of Control (as hereinafter defined); and
C. The parties desire to provide an incentive for the continued
employment of the Executive in order to facilitate a potential Change of
Control.
NOW, THEREFORE, the parties agree as follows:
1. Definitions. For purposes of this Agreement, the following terms
shall be defined as follows:
1.1 "Cause" shall exist in the event of the Executive's (i)
willful and repeated neglect of his duties as an employee of the Company (other
than as a result of a physical disability not related to substance abuse), (ii)
conviction of a crime involving moral turpitude, (iii) commission of any act of
fraud or dishonesty against the Company, or (iv) breach of the Executive's
obligations under any employment agreement or Proprietary Information and
Inventions Agreement between the Executive and the Company which, if curable, is
not cured within ten (10) days following notice of such breach by the Company.
1.2 A "Change of Control" of the Company shall occur upon: (i) a
merger, consolidation or other reorganization involving the Company, or a tender
offer, exchange offer or other transaction or series of transactions involving
the acquisition of securities of the Company where, in any such case, the
holders of voting securities of the Company immediately prior to such
transaction or series of transactions own less than 50% of the voting securities
of the surviving or successor entity, or its parent, immediately following such
transaction or series of transactions; (ii) the sale of all or substantially all
of the Company's assets; or (iii) the sale of all or substantially all of the
capital stock or assets of any subsidiary or subsidiaries of the Company which
accounted for 40% or more of the Company's consolidated revenues for the
preceding fiscal year.
1.3 "Good Reason" shall exist in the event that, other than under
circumstances involving Cause or the Executive's total disability (as defined
pursuant to the Company's long-term disability insurance plan covering the
Executive if any such plan is then in effect, or otherwise as determined by the
Company's Board of Directors), the Company, without the Executive's prior
written consent; (i) materially alters or reduces the Executive's duties,
responsibilities and status with the Company from those which exist as of the
Effective Date of
this Agreement; (ii) reduces the level of compensation or benefits that the
Executive is earning as an employee of the Company; (iii) requires the Employee,
as a condition to his continued employment, to be based more than 100 miles from
the location where he is based as of the Effective Date; or (iv) requires the
Employee, as a condition to his continued employment, to perform illegal or
fraudulent acts or omissions.
1.4 A "Qualifying Employment Agreement" shall mean a written
agreement for the continued employment by the Executive in a position with
duties and responsibilities substantially comparable to his current position,
with compensation and other benefits substantially comparable, in the aggregate,
to his current compensation and benefits, and providing for a term of at least
one year and severance benefits equal to at least one-half of his annual base
salary in the event of his involuntary termination other than for Cause or his
voluntary termination for Good Reason.
2. Retention and Severance Arrangement.
2.1 Retention Bonus. In the event the Company effects a Change of
Control during the term of this Agreement, the Executive shall be entitled to
receive a cash bonus (the "Retention Bonus") in an amount equal to one-half of
his then-effective annual base salary, payable in a single lump sum promptly
upon the fulfillment of the conditions set forth in Section 2.2.
2.2 Conditions to Receipt of Retention Bonus.
(a) In order for the Executive to be eligible to receive
the Retention Bonus, the following conditions must be met:
(i) The Executive must be continuously employed by
the Company on a full-time basis between the Effective Date of this Agreement
and the effective date of the Change of Control; and
(ii) Either of the following conditions must occur:
(A) the Executive remains continuously employed by the Company, Raytel Cardiac
Services, Inc., the acquiring entity or another subsidiary or affiliate of the
acquiring entity during the six-month period following the effectiveness of the
Change of Control (provided, however, that no Retention Bonus shall be payable
if, during such six-month period, the Executive and one or more of such entities
enter into a Qualifying Employment Agreement); or (B) prior to the end of such
six-month period, the Executive's employment by one of such entities is
terminated involuntarily by such entity other than for Cause or voluntarily by
the Executive with Good Reason.
2.3 Reduction. The Retention Bonus payable to the Executive shall
be reduced by an amount equal to any severance payments paid to the Executive
under the terms of any Company policy regarding severance benefits or any
employment agreement between the Executive and the Company, not including the
value associated with any acceleration of vesting of options or stock as a
result of a Change of Control.
2
2.4 Acceleration of Option Vesting. The option agreements between
the Company and the Executive shall be amended to provide that the vesting
provisions of all outstanding options to purchase the Company's Common Stock
held by the Executive shall be accelerated so that such options will vest and
become exercisable, in full, upon the Change of Control, to the extent any such
option agreements do not currently provide for such acceleration of vesting.
2.5 Annual Bonus. The Retention Bonus is not intended to replace
or reduce any bonus to which the Executive may be entitled under the Company's
existing annual incentive bonus program, which shall continue to be administered
in accordance with the Company's existing policies.
2.6 Not an Employment Agreement. The Executive is currently
employed as an "at will" employee. This Key Management Retention Agreement is
not an employment agreement, and nothing contained herein shall limit the rights
of the Company or the Employee to terminate the Employee's employment at any
time for any reason.
2.7 Term. The term of this Agreement shall be twelve (12)
calendar months from the Effective Date of this Agreement.
3. General
3.1 Successors and Assigns. The provisions of this Agreement
shall inure to the benefit of and be binding upon the Company, the Executive and
each and all of their respective heirs, legal representatives, successors and
assigns. The duties, responsibilities and obligations of the Executive under
this Agreement shall be personal and not assignable or delegable by the
Executive in any manner whatsoever to any person, corporation, partnerships,
firm, company, joint venture or other entity. The Executive may not assign,
transfer, convey, mortgage, pledge or in any other manner encumber the
compensation or other benefits to be received by him or any rights which he may
have pursuant to the terms and provisions of this Agreement. The Company
covenants and agrees to require that any successor to the Company through a
Change of Control shall agree to honor the obligations of the Company under this
Agreement.
3.2 Waiver. No waiver of any breach of any warranty,
representation, agreement, promise, covenant, paragraph, term or provision of
this Agreement shall be deemed to be a waiver of any preceding or succeeding
breach of the same or any other warranty, representation, agreement, promise,
covenant, paragraph, term or provision of this Agreement. No extension of the
time for the performance of any obligation or other act required or permitted by
this Agreement shall be deemed to be an extension of the time of the performance
of any other obligation or any other act required or permitted by this
Agreement.
3.3 Entire Agreement. This Agreement, and the other agreements
referred to herein, including the Company's benefit plans, are the sole,
complete and entire contract, agreement and understanding between the Company
and the Executive concerning the subject matter hereof. Except as otherwise
provided herein, this Agreement supersedes any and all prior
3
contracts, agreements, plans, agreements in principle, correspondence, letters
of intent, understandings, and negotiations, whether oral or written, concerning
the subject matter hereof.
3.4 Amendments. No amendment, modification, waiver, or consent
relating to this Agreement will be effective unless and until it is embodied in
a written document signed by the Company and by the Executive.
3.5 Counterparts. The Agreement may be executed by the Company
and by the Executive in counterparts, each of which shall be deemed an original
and which together shall constitute one instrument.
3.6 Headings. The headings contained in this Agreement are for
reference purposes only and shall not in any manner whatsoever affect the
construction or interpretation of this Agreement or be deemed a part of this
Agreement for any purpose whatsoever.
3.7 Severability. To the extent that any section, term,
provision, sentence, phrase, clause or word of this Agreement shall be found to
be illegal or unenforceable for any reason, such section, term, provision,
sentence, phrase, clause or word shall be modified or deleted in such a manner
as to make this Agreement, as so modified, legal and enforceable under
applicable laws. The remainder of this Agreement shall continue in full force
and effect.
3.8 Applicable Law. This Agreement and each and every provision
of this Agreement shall be interpreted solely pursuant to the internal laws of
the State of California without regard to any conflicts of law principles
thereof.
3.9 Construction. The language of this Agreement shall for all
purposes be construed as a whole, according to its fair meaning, not strictly
for or against the Executive or the Company, without regard to the identity or
status of any person or persons who drafted all or any portion of this
Agreement.
3.10 Notices. Any notices to be given pursuant to this Agreement
by either party to the other party may be effected by personal delivery or by
registered or certified mail, postage prepaid with return receipt requested.
Mailed notices shall be addressed to the parties at the addresses stated below,
but each party may change its or his address by written notice to the other in
accordance with this Section 3.10. Notices delivered personally shall be deemed
received on the date of delivery. Notices delivered by mail shall be deemed
received on the third business day after the mailing thereof.
Mailed notices to the Executive shall be addressed as follows:
Xxxx X. Xxxxxx, Xx.
00 Xxxxxx Xxxx
Xxxxxxx, Xxxxxxxxxxx 00000
Mailed notices to the Company shall be addressed as follows:
4
Raytel Medical Corporation
0000 Xxxxxx Xxxxx, Xxxxx 000
Xxx Xxxxx, Xxxxxxxxxx 00000-0000
Attention: Chief Executive Officer
3.11 Arbitration. Any and all controversies, disputes and/or
claims in any manner arising out of or relating to this Agreement shall be
settled solely be arbitration in accordance with the Commercial Arbitration
Rules of the American Arbitration Association. Such arbitration proceeding shall
take place in the state and county of the Company's office where the Executive
is based. Judgment on any decision rendered by the arbitrator may be entered in
any court having jurisdiction thereof. Each party shall bear its own attorney's
fees and expenses and other costs in any arbitration proceeding. All
administrative fees and the fee of the arbitrator shall be borne by the parties
equally. The arbitration provisions set forth in this Section 3.11 are intended
by the Executive and by the Company to be absolutely exclusive for all purposes
whatsoever, and applicable to each and every controversy, dispute or claim in
any manner arising out of or relating to this Agreement, the meaning,
application or interpretation of this Agreement, any breach or claimed breach
thereof or any voluntary or involuntary termination of this Agreement with or
without cause, including, without limitation, any such controversy, dispute or
claim which, if pursued through any state or federal court or administrative
agency, would arise at law, in equity or pursuant to statutory, regulatory or
common law rules, regardless of whether such dispute, controversy or claim would
arise in or from contract, tort or any other legal or equitable theory or basis.
IN WITNESS WHEREOF, the Company and the Executive have executed this
Agreement as of the date first set forth above.
RAYTEL MEDICAL CORPORATION
By:_____________________________________ __________________________________
Xxxxxxx X. Xxxxx Xxxx X. Xxxxxx, Xx.
Chairman and Chief Executive Officer
5